皮肤癌：T-VEC溶瘤病毒疗法在黑色素瘤治疗中显示出前景。 - Suppr

Suppr

超能文献

Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma.

作者信息

Killock David

出版信息

Nat Rev Clin Oncol. 2015 Aug;12(8):438. doi: 10.1038/nrclinonc.2015.106. Epub 2015 Jun 16.

DOI:10.1038/nrclinonc.2015.106

PMID:26077044

Abstract

摘要

相似文献

Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma.皮肤癌：T-VEC溶瘤病毒疗法在黑色素瘤治疗中显示出前景。

Nat Rev Clin Oncol. 2015 Aug;12(8):438. doi: 10.1038/nrclinonc.2015.106. Epub 2015 Jun 16.

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.替莫唑胺胶丸联合放疗治疗恶性脑胶质瘤的疗效观察

J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.

Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.talimogene laherparepvec（T-VEC）的临床开发：一种源自1型单纯疱疹病毒的改良溶瘤免疫疗法。

Expert Rev Anticancer Ther. 2015;15(12):1389-403. doi: 10.1586/14737140.2015.1115725.

Talimogene laherparepvec (T-VEC) as cancer immunotherapy.塔利莫基因拉罗韦克（T-VEC）作为癌症免疫疗法。

Drugs Today (Barc). 2015 Sep;51(9):549-58. doi: 10.1358/dot.2015.51.9.2383044.

Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma.溶瘤病毒动力学机制模型分析替莫唑胺拉帕替尼（T-VEC）在晚期黑色素瘤患者中作为一类首创的溶瘤病毒治疗药物的疗效。

CPT Pharmacometrics Syst Pharmacol. 2023 Feb;12(2):250-260. doi: 10.1002/psp4.12898. Epub 2023 Jan 11.

The safety of talimogene laherparepvec for the treatment of advanced melanoma.talimogene laherparepvec治疗晚期黑色素瘤的安全性。

Expert Opin Drug Saf. 2017 Feb;16(2):265-269. doi: 10.1080/14740338.2017.1274729. Epub 2016 Dec 28.

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.分子途径：新型溶瘤病毒免疫疗法塔利莫基因拉帕里韦克的作用机制

Clin Cancer Res. 2016 Mar 1;22(5):1048-54. doi: 10.1158/1078-0432.CCR-15-2667. Epub 2015 Dec 30.

Oncolytic virus immunotherapy for melanoma.溶瘤病毒免疫疗法治疗黑色素瘤。

Curr Treat Options Oncol. 2015 Mar;16(3):326. doi: 10.1007/s11864-014-0326-0.

An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions.替莫唑胺胶囊治疗神经胶质瘤的临床疗效及安全性评价

Am J Clin Dermatol. 2020 Dec;21(6):821-832. doi: 10.1007/s40257-020-00554-8.

High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a).T-VEC 在早期转移性黑色素瘤（IIIb/C 期/IVM1a）中具有高缓解率。

Int J Cancer. 2019 Aug 15;145(4):974-978. doi: 10.1002/ijc.32172. Epub 2019 Feb 21.

引用本文的文献

Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook.溶瘤单纯疱疹病毒疗法：最新进展、核心挑战与未来展望。

Vaccines (Basel). 2025 Aug 20;13(8):880. doi: 10.3390/vaccines13080880.

Suppression of multiple mouse models of refractory malignancies by reprogramming IL-18 ligand-receptor interaction.通过重编程白细胞介素-18配体-受体相互作用抑制难治性恶性肿瘤的多种小鼠模型

Nat Commun. 2025 Jul 3;16(1):6136. doi: 10.1038/s41467-025-61439-0.

An oncolytic virus-T cell chimera for cancer immunotherapy.一种用于癌症免疫治疗的溶瘤病毒-T细胞嵌合体。

Nat Biotechnol. 2024 Dec;42(12):1876-1887. doi: 10.1038/s41587-023-02118-7. Epub 2024 Feb 9.

Current status of skin cancers with a focus on immunology and immunotherapy.聚焦免疫学与免疫疗法的皮肤癌现状

Cancer Cell Int. 2023 Aug 21;23(1):174. doi: 10.1186/s12935-023-03012-7.

Development and application of oncolytic viruses as the nemesis of tumor cells.溶瘤病毒作为肿瘤细胞克星的研发与应用。

Front Microbiol. 2023 Jun 12;14:1188526. doi: 10.3389/fmicb.2023.1188526. eCollection 2023.

esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation.表达esRAGE的溶瘤单纯疱疹病毒通过抑制内皮细胞活化增强抗肿瘤疗效。

Mol Ther Oncolytics. 2023 Jan 16;28:171-181. doi: 10.1016/j.omto.2023.01.003. eCollection 2023 Mar 16.

Metabolic heterogeneity protects metastatic mucosal melanomas cells from ferroptosis.代谢异质性保护转移性黏膜黑色素瘤细胞免受铁死亡。

Int J Mol Med. 2022 Oct;50(4). doi: 10.3892/ijmm.2022.5180. Epub 2022 Aug 25.

The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVΔ51 via aggravating endoplasmic reticulum stress.磷酸肌醇 3-激酶抑制剂 ZSTK474 通过加重内质网应激增加骨肉瘤细胞对溶瘤性单纯疱疹病毒 VSVΔ51 的敏感性。

Bioengineered. 2021 Dec;12(2):11847-11857. doi: 10.1080/21655979.2021.1999372.

Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes.利用工程化溶瘤痘苗病毒重塑肿瘤微环境可改善 PD-L1 抑制效果。

Biosci Rep. 2021 Jun 25;41(6). doi: 10.1042/BSR20204186.

The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.癌症诊断、治疗和监测的未来：免疫疗法和免疫 PET 放射性示踪剂的系统评价。

Molecules. 2021 Apr 11;26(8):2201. doi: 10.3390/molecules26082201.

本文引用的文献

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.替莫唑胺胶丸联合放疗治疗恶性脑胶质瘤的疗效观察

J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验